Intellectual Property Committee

Annual report, FY18

Prepared by P. Shamsi, chair, Aug. 22, 2018

Annual meeting:
Date: Oct. 10, 2017
Meeting minutes:

- Keith Strassner updated the committee regarding the activities of the tech transfer office during FY17
- The committee considered a new streamlined process for the faculty to get an IP agreement with S&T on their inventions (details in the following section)
- Patent/technology transfer figures for FY17 are attached.

Policy Recommendation for Express License Initiative:
IP committee was very interested in a unified process for S&T faculty to be able to get easy IP agreements with S&T on their inventions/IPs. The main goal of this procedure is to promote entrepreneurial activities. Currently, this procedure is being investigated and pursued by the office of tech. transfer (Keith Strassner) and has not been approved yet. Hence, no more details are available at this point. However, a short description of the proposed procedure reads:

“University of Missouri’s Express License initiative is a fast track process that will allow faculty entrepreneurs to focus their time, efforts, and resources on the development and commercialization of University technology. This Express License is designed streamline the contract negotiation process and replace it with a license predefined set of terms and conditions. The terms are based on the idea of shared success and meant to encourage entrepreneurial efforts at the University of Missouri.”
Report to
Patent Committee
October 2017

Office of Technology Transfer
and Economic Development

ecodevo.mst.edu | businessdevelopment.mst.edu | techtransfer.mst.edu
Mariesa Crow  
VPR

Keith Strassner  
Director, OTTED

Deena Aaron  
Administrative Assistant

Travin Shelton  
Business Development Specialist

Karen Leatherman  
Business Development Specialist

John Woodson  
Senior Licensing Associate

Casey Gideon-Saladin  
Para-Legal/Business Manager

Tech Development Center, NSF AWARE: ACCESS, UM Extension, OSP contract support

Small Business Technology Development Center

Technology Transfer
Funding

• **Technology Transfer**
  – Campus funding and portion of royalty income for office operations
  – Unreimbursed patent expenses from “System Share” of royalty income
  – Majority of royalty income will be used for Special Projects, Technology Acceleration Program

• **SBTDC**
  – UM Extension funding used as match on SBTDC statewide grant (declining contribution for last 3 years) currently 0.5FTE supplemented with campus funds

• **OTTED**
  – Campus funding and external grants (Missouri Enterprise, MTC MOBEC, USDA, NSF)
Results (FY17)

• **Technology Transfer**
  – Royalty Income
    • Record Income $540K
    • Strong steady increases each year
    • Over $4MM since 2005
  – Patents/Copyrights Issued
    • 15 in FY17
  – Disclosures Received
    • 47 in FY17, consistently above 40
  – Active License/options
    • 32 Licenses
    • 3 pending
  – Active Case load
    • 173 cases
  – Patent expenses
    • $351K total patent expenses
    • $235K unreimbursed
    • $108K repaid by licensee

• **SBTDC YTD (Oct-Sept)**
  – Investments
    • $3.5M
  – Jobs created
    • 122
  – Business Starts
    • 17
  – Active Clients
    • 322

• **Tech Development Center**
  – 23 tenants (including virtual tenants)
  – Building still operates at slight loss
## TTO Comparable Schools

### 2015 last year available from AUTM (Based on 3 year 2013-2015 average)

<table>
<thead>
<tr>
<th>Metric</th>
<th>S&amp;T</th>
<th>S&amp;T Rank</th>
<th>Colorado School of Mines</th>
<th>Michigan Tech</th>
<th>New Jersey Tech</th>
<th>Stevens</th>
<th>Georgia Tech</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invention disclosures (3 year ave)</td>
<td>44</td>
<td>3</td>
<td>41</td>
<td>43</td>
<td>57</td>
<td>51</td>
<td>301</td>
</tr>
<tr>
<td>Disclosure/million in research (3 year ave)</td>
<td>1.25</td>
<td>2</td>
<td>0.69</td>
<td>0.62</td>
<td>0.53</td>
<td>1.78</td>
<td>0.40</td>
</tr>
<tr>
<td>Gross license income (3 year ave)</td>
<td>$357,242.00</td>
<td>1</td>
<td>$101,992.00</td>
<td>$233,490.00</td>
<td>$137,455.00</td>
<td>$262,333.00</td>
<td>$1,838,515.00</td>
</tr>
<tr>
<td>Ave income/license (3 year ave)</td>
<td>$25,157.89</td>
<td>2</td>
<td>$4,031.30</td>
<td>$9,120.70</td>
<td>$4,789.37</td>
<td>$131,166.50</td>
<td>$27,730.24</td>
</tr>
<tr>
<td>License income/million research (3 year ave)</td>
<td>$10,206.00</td>
<td>1</td>
<td>$1,705.00</td>
<td>$3,354.00</td>
<td>$1,273.00</td>
<td>$9,058.00</td>
<td>$2,420.00</td>
</tr>
<tr>
<td>Patents issued (3 year ave)</td>
<td>11.3</td>
<td>2</td>
<td>8.7</td>
<td>4.7</td>
<td>20.3</td>
<td>6.0</td>
<td>92.0</td>
</tr>
<tr>
<td>Patents issued per disclosure</td>
<td>0.26</td>
<td>2</td>
<td>0.21</td>
<td>0.11</td>
<td>0.36</td>
<td>0.12</td>
<td>0.31</td>
</tr>
</tbody>
</table>
Opportunities/Challenges

• Diverse Royalty Income base;
  – non-chrome coatings
  – wound care
  – Super-capacitors
  – Microwave Imaging

• Invention disclosures remain high (FY18 already 19 new disclosures)
• Strong partnerships with our licensees (PPG will license 3 new technologies)
• Portfolio approach in managing patents
• New funding to support early stage technology development

• Non-Royalty producing Technology Transfer increasing
  – Consortium developed inventions – NERF, patent costs covered
  – “BPM-203” inventions – Upcharge on F&A is low (15%), none of the funds flow to the TTO

• Lack of Gap Funding source for faculty/graduate student start-ups
• Dramatic increase ($125 \rightarrow \$3,000+) in costs for provisional filings
Borate based Bio-Glass

License Income Received to date: $590,819

Global market for wound care is $4 Billion

FDA approved and launched in April 2017

22 US and Foreign patent applications

15 issued patents (12 US, 3 foreign)
7 pending (1 US, 6 foreign)

2 Licenses to mo-sci for human use

mo-sci direct market Mirragen™ Advanced Wound Matrix

Sublicense to Ultradent for dental care

Sublicense to Prosidyan for bone repair

License to RediHeal for Veterinary use

License Income Received to date: $590,819

Global market for wound care is $4 Billion

FDA approved and launched in April 2017